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Abstract
Data on genome damage, lipid peroxidation, and levels of glutathione peroxidase (GPX) in newborns after transplacental
exposure to xenobiotics are rare and insufficient for risk assessment. The aim of the current study was to analyze, in an animal
model, transplacental genotoxicity, lipid peroxidation, and detoxification disturbances caused by the following drugs commonly
prescribed to pregnant women: paracetamol, fluconazole, 5-nitrofurantoin, and sodium valproate. Genome damage in dams
and their newborn pups transplacentally exposed to these drugs was investigated using the in vivo micronucleus (MN) assay.
The drugs were administered to dams intraperitoneally in three consecutive daily doses between days 12 and 14 of pregnancy.
The results were correlated, with detoxification capacity of the newborn pups measured by the levels of GPX in blood and lipid
peroxidation in liver measured by malondialdehyde (HPLC-MDA) levels. Sodium valproate and 5-nitrofurantoin significantly
increased MN frequency in pregnant dams. A significant increase in the MN frequency of newborn pups was detected for all
drugs tested. This paper also provides reference levels of MDA in newborn pups, according to which all drugs tested
significantly lowered MDA levels of newborn pups, while blood GPX activity dropped significantly only after exposure to
paracetamol. The GPX reduction reflected systemic oxidative stress, which is known to occur with paracetamol treatment. The
reduction of MDA in the liver is suggested to be an unspecific metabolic reaction to the drugs that express cytotoxic, in
particular hepatotoxic, effects associated with oxidative stress and lipid peroxidation.
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Introduction
Limited data are available on the mechanisms of
transplacental genotoxicity and detoxification in the fetus
during intrauterine development. Transplacental exposure
to xenobiotics may disturb developmental homeostasis
and cause physiological stress and genome damage in
the fetus, with a lifelong increase in health risks for
different diseases (1). In addition to environmental
exposure and diet, drug intake during pregnancy could
have a significant impact on the genomic and nongenomic
pathways of fetal development. Although the teratogenic
effect of many drugs has been described, the mechan-
isms and contribution to genome damage etiology have
not been elucidated.
During pregnancy the metabolism in women changes
(2), as reflected in specific biological effects of drugs and
environmental stressors. Drug metabolism may produce
reactive oxygen species, which cause oxidative damage
to DNA, RNA, lipids, and proteins via superoxide anion,
hydrogen peroxide, and hydroxyl radicals (3). Lipid
peroxidation is a process also triggered by free radicals,
which results in the degradation of polyunsaturated fatty
acids (4). The lipid peroxidation end-products malondial-
dehyde (MDA) and 4-hydroxy-2-nonenal (HNE) adversely
affect genome integrity, causing DNA strand breaks,
formation of DNA adducts, increased frequency of sister
chromatid exchange, and apoptosis (5,6).
Drugs and/or their metabolites can accumulate in the
tissues of the fetus in a different way than in adults,
because of the specific metabolism and high tissue
proliferation rate in the fetus (7). The dynamic balance
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between Phase I and II drug-metabolizing enzymes
influences the toxic effects of agents metabolized at
different stages of development and consequently the
timing and level of DNA damage (8). The levels of
glutathione-related antioxidant enzymes differ signifi-
cantly in fetal and adult rat liver, with very low activity
during the perinatal period (9).
Differences in enzymatic systems, pharmacokinetics,
and clearance capacity between the fetus and adult
render simple extrapolation of results obtained in adult
organisms prone to errors when assessing fetal health
risk after exposure to xenobiotics (10).
The animal model of transplacental exposure can
significantly elucidate involved mechanisms and give
insight into the health risks associated with drugs whose
metabolites and doses are known from clinical practice.
Such results can also contribute to the investigation of
health effects after transplacental exposure to environ-
mental xenobiotics.
In animal studies on pregnant dams, paracetamol
has been shown to cause liver and kidney ultrastruc-
tural changes after long-term treatment (11), whereas
5-nitrofurantoin has also been shown to be genotoxic
(12) and is associated with birth defects (13). The
management of epilepsy in pregnant women requires
careful monitoring, because antiepileptic drugs such as
sodium valproate are related to teratogenicity and
oxidative stress and a decrease in antioxidants such as
vitamin E and glutathione peroxidase (GPX) (14,15).
Although no increased risk of malformations was found
in a population-based study after treatment with the
antifungal drug fluconazole (16), in animal models it
has been shown to be transplacentally genotoxic and
was associated with embriotoxic and teratogenic
effects (17,18).
The aim of the present study was to measure genome
damage in newborn pups transplacentally exposed to
selected drugs often used during pregnancy (19-22),
using an in vivo micronucleus (MN) assay (23), and to
compare the results with levels of GPX and MDA. The
drugs used in the current study to treat the pregnant mice
were analgesic/antipyretic (paracetamol), antifungal (flu-
conazole), antibiotic (5-nitrofurantoin), and antiepileptic
(sodium valproate). Additionally, because antibiotics and
paracetamol are frequently prescribed simultaneously,
the combination of 5-nitrofurantoin and paracetamol was
also investigated, in order to detect possible synergistic or
antagonistic mechanisms in the case of combined
exposure. It is known that paracetamol, fluconazole,
sodium valproate, 5-nitrofurantoin, and cyclophospha-
mide (CP) cross the placenta (24-29). Applied doses of
drugs were taken from maximal daily doses in human
medical practice (30). Administration of the drugs to dams
was performed for 3 days, from days 12 through 14 of
pregnancy, in order to target the period of major
organogenesis in mice (31).
Material and Methods
This study included 56 2-month-old BALB/c dams
(Charles River, Germany), randomized into 7 groups, and
their newborn pups. The mice were obtained from the
breeding colony at the Rudjer Boskovic Institute (Zagreb,
Croatia). Dams were kept with the litter in separate cages
under the following conditions: temperature 22±26C,
relative humidity 55±10%, with about 15-20 air changes
per hour and a 12:12-h light/dark cycle. All animals had
access to food and water ad libitum. All experiments were
performed according to the ILAR Guide for the Care and
Use of Laboratory Animals, Council Directive (86/609/
EEC) and the Croatian Animal Welfare Act (NN 19/99).
This study was approved by the Croatian Ministry of
Agriculture (Veterinary Department, Ethics Committee
approval No. 525-06-05-02).
Drug administration
Five groups of pregnant dams received the following
pharmaceutical products: 5-nitrofurantoin (Sigma, USA),
fluconazole (Sigma), paracetamol (Belupo, Croatia), 5-
nitrofurantoin (Sigma), and sodium valproate (Krka,
Slovenia). One group received a combination of 5-
nitrofurantoin and paracetamol. The positive control group
received CP (Sigma), and the negative control group
received physiological saline (Kemika, Croatia). There
were eight dams in each group.
The administered volume for each compound was
5 mL/kg. The drug doses (Table 1) were based on
recommended human doses (30). Preliminary studies
had shown that the positive control of 10 mg/kg CP was
suitable for studying transplacental genotoxicity, as it
shows a significant increase in MN frequency but not
significant fetotoxicity. All drugs were administered
intraperitoneally in three consecutive daily doses on days
12 to 14 of pregnancy, except CP, which was admini-
strated in a single dose. Samples were taken from the
dams 48 h after drug administration for in vivo MN
assays.
In each litter, 6 animals were analyzed using an in vivo
MN assay, GPX activity, and MDA analysis. Blood
samples were taken for the in vivo MN assay and
glutathione, and liver samples were taken for MDA
measurement. Dams and newborn pups were killed after
delivery.
In vivo MN testing
Peripheral blood (5 mL) was collected from the tail vein
of pregnant dams on day 12 of pregnancy and 48 h after
drug administration. Neonatal genotoxicity in pups was
analyzed from 6 to 18 h after delivery. Blood was smeared
on an acridine orange-coated slide (Molecular Probes,
USA), covered with a cover slip, and analyzed according
to Hayashi et al. (23). For each animal, 1000 reticu-
locytes were analyzed using a fluorescent microscope
Damage after transplacental exposure to pharmaceutical drugs 1015
www.bjournal.com.br Braz J Med Biol Res 46(12) 2013
(Olympus, Japan).
Determination of GPX activity
Blood GPX activity was analyzed from whole blood
with a UV method using the commercial Ransel kit
(Randox Laboratories, UK) and an automated analyzer
(Olympus AU 560). The following reagents were used:
reagent 1 (glutathione, glutathione reductase, and
NADPH) was prepared by dissolving one vial in 8 mL of
respective buffer 2. Reagent 2 was prepared freshly
before use by dissolving in 52 mL of twice-distilled water
with 10 mL cumene hydroperoxide and by stirring the
mixture at room temperature.
The dilution reagent for the samples was prepared by
dissolving one vial in 200 mL twice-distilled water. The
assay was calibrated according to the manufacturer’s
instructions using control Ransel GPX samples. The
samples were diluted further with the dilution reagent
initially at a 1:40 ratio and afterward at a 1:10 ratio before
analysis. The automated analyzer processed the samples
according to the previous assay parameters, giving a
linear standard curve with 840 U/L maximum.
MDA analysis
Fresh liver samples were cut in small pieces and
placed in Eppendorf vials to be frozen at –806C before
analysis. The samples were defrosted and their wet
weight measured before homogenization in 900 mL
phosphate-buffered saline containing 100 mL 0.5% butyl-
ated hydroxytoluene (Aldrich, USA) prepared in ethanol.
Homogenates (25 mL) prepared this way were kept in
Eppendorf vials at –806C until MDA analysis.
MDA standards were prepared with 1,1,3,3-tetra-
ethoxypropane (Sigma) as 0, 0.31, 0.63, 1.25, 2.5, 5,
and 10 mM solutions. Briefly, 25-mL samples were mixed
with 225 mL water, 375 mL 0.44 mM H3PO4 (Kemika), and
125 mL 42 mM thiobarbituric acid (Sigma) and were boiled
at 1006C for 60 min and then cooled on ice. Upon cooling,
alkaline methanol was added to the samples in a 1:1 ratio.
The samples were centrifuged for 20 min at 3619 g, and
supernatants were analyzed at once. MDA was deter-
mined using an HPLC System Gold 128 analyzer
(Beckman, Germany) with Midas auto-sampler (Spark,
Holland) and Shimadzu RF-535 fluorescent detector
(Shimadzu, Japan) with 527-nm excitation and 550-nm
emission. The mobile phase consisted of 50 mM KH2PO4
(Kemika), pH 6.8, and 40% (v/v) methanol (Merck,
Germany), with a 1 mL/min flow applied for 100-mL
samples analyzed on a Spherisorb column ODS2, 5 mm,
4.66150 mm (Walters, USA).
Statistical analysis
Analysis of variance (ANOVA) for repeated measure-
ments was used to compare responses, as a function of
dose at each sampling time, and their interactions. Where
ANOVA demonstrated a significant difference, we ran the
post hoc LSD test of multiple comparisons to accurately
determine to which doses and groups this significant
difference applied. Statistical significance was set at
P#0.05 (Statistica 6.0, USA).
Results
In vivo MN assay in pregnant dams
Baseline MN frequency in dams on day 12 of
pregnancy was 0.86±0.90 per 1000 reticulocytes. CP
induced the highest MN frequency (8.50±1.70 MN per
1000 reticulocytes) 48 h after administration. Significantly
higher MN frequencies were observed 48 h after the
administration of 5-nitrofurantoin and sodium valproate
(4.13±1.96 and 5.17±1.17 per 1000 reticulocytes,
respectively; Table 2). Fluconazole and paracetamol did
not increase the MN frequency. No significant difference
was observed between the group receiving a combination
of 5-nitrofurantoin and paracetamol and the groups
treated with 5-nitrofurantoin or paracetamol alone.
In vivo MN assay in pups
In newborn pups transplacentally exposed to CP, MN
frequency was 2.40±1.34 per 1000 reticulocytes. In
newborn pups of dams exposed to physiological saline,
the MN frequency was 1.67±1.03 per 1000 reticulocytes.
All drugs tested increased the MN frequency in newborn
pups. MN frequencies for each compound tested are
shown in Table 2. The highest MN frequency in pups was
caused by fluconazole (5.58±0.79 per 1000 reticulocytes).
Table 1. Concentration of drugs used in the study.
Group Drug (solvent) Molecular formula Dose (mg/kg)
1 Physiological saline NaCl
2 Cyclophosphamide (saline) C7H15Cl2N2O2P 10 (single)
3 5-Nitrofurantoin (dimethyl cellulose) C8H6N4O5 50
4 Fluconazole (saline) C13H12F2N6O 12
5 Paracetamol (saline) C8H9NO2 60
6 5-Nitrofurantoin (dimethyl cellulose)/paracetamol
(saline)
C8H6N4O5/C8H9NO2 50/60
7 Sodium valproate (saline) C8H15NaO2 100
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No significant difference was observed between the
group receiving the combination of 5-nitrofurantoin and
paracetamol and the groups treated with 5-nitrofurantoin
or paracetamol alone. Not a single animal showed
malformations and no stillborns were detected.
Biochemical analysis
GPX. GPX activity in the hemolysate of newborn pups
ranged from 1588.33 to 2561.67 U/L. In the saline control
group, it was 2134.29 U/L. Only the paracetamol and 5-
nitrofurantoin+paracetamol groups were significantly
different (P#0.05) from the control (Table 3).
MDA. Liver MDA concentrations in newborn pups
ranged from 83.71 to 233.83 pmol/kg. All groups showed
a significant difference (P,0.05) from the saline control
(233.83 pmol/kg). Group 6 (5-nitrofurantoin+paracetamol)
did not differ significantly from Group 3 (5-nitrofurantoin
alone) or Group 5 (paracetamol alone; Table 3).
Discussion
There are many gaps in the knowledge about
metabolic disturbances and genome damage in fetuses
of women taking drugs during pregnancy. Any linear
correlation of the biological effects of transplacental drugs
and health risks with the adult population would disregard
specific biological and pharmacological interactions perti-
nent to fetal development. A causal relationship between
genotoxic agents and increased risk of cancer has been
evidenced by animal and epidemiological studies (32). In
order to elucidate the transplacental effects of drugs
commonly prescribed during pregnancy, we used an
animal model to estimate the genome damage in
pregnant mice and their pups. Additionally, genome
damage, measured in vivo with the MN assay, was
compared with detoxification capacity and the level of lipid
peroxidation in newborn mice. This is also the first
comprehensive study of GPX and MDA levels in mice
exposed to xenobiotics during fetal development, and
provides referral control values for the respective para-
meters of major antioxidant metabolism and lipid perox-
idation in mice.
Whyatt et al. (33) have shown that glutathione
transferase activity is critical for interpretation of DNA
damage in maternal and newborn white blood cells after
exposure to urban pollution. Low glutathione levels and
Table 2. Micronucleus frequency in pregnant mice and newborn pups (6-18 h after delivery), transplacentally exposed to the drugs
tested and physiological saline.
Drug Pregnant mice Pups
0 h 48 h 6-18 h
Negative control 0.86 ± 0.90 1.00 ± 0.58 1.67 ± 1.03
Positive control 1.38 ± 0.74 8.50 ± 1.70* 2.40 ± 1.34
5-Nitrofurantoin 1.13 ± 0.83 4.13 ± 1.96* 5.00 ± 1.00*
Fluconazole 1.44 ± 0.73 2.11 ± 1.45 5.58 ± 0.79*
Paracetamol 1.00 ± 0.76 3.25 ± 2.19 3.80 ± 1.10*
5-Nitrofurantoin+ paracetamol 1.00 ± 0.76 4.50 ± 1.07* 5.00 ± 0.63*
Sodium valproate 1.33 ± 0.52 5.17 ± 1.17* 5.20 ± 1.48*
Data are reported as means±SD per 1000 reticulocytes. Negative control: physiological saline; positive control: cyclophosphamide.
* P#0.05 compared to baseline values (ANOVA).
Table 3. Glutathione peroxidase (GPX) and malondialdehyde (MDA) levels (6-18 h after delivery) of the newborn mice transplacentally
exposed to the drugs tested or saline.
Group Drug GPX (U/L) MDA (pmol/kg)
1 Negative control 2134.29 ± 320.36 233.83 ± 79.90
2 Positive control 2336.00 ± 277.27 107.60 ± 19.01*
3 5-Nitrofurantoin 2296.25 ± 488.46 112.38 ± 44.04*
4 Fluconazole 2198.33 ± 576.73 146.71 ± 36.25*
5 Paracetamol 1588.33 ± 408.58* 121.50 ± 36.42*
6 5-Nitrofurantoin+ paracetamol 1667.14 ± 410.15* 83.71 ± 41.54*
7 Sodium valproate 2561.67 ± 552.36 96.00 ± 54.93*
Data are reported as means±SD. Negative control: physiological saline; positive control: cyclophosphamide. * P#0.05 compared to
saline control for GPX and MDA (post hoc LSD test).
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high glutathione disulfide/glutathione ratios have been
associated with various illnesses (34). Tissue-specific and
developmental variations in glutathione S-transferase
(GST) mRNA expression were demonstrated in human
prenatal liver, where total GPX and GST-dependent
peroxidase activities were 9 to 18 times lower than in
the adult liver (34).
Because the major part of fetal hematopoiesis occurs
in the liver, we believe that the data obtained from
peripheral blood hemolysate in our model are related to
the onset of oxidative stress in the liver tissue. As shown
by Gehringer et al. (35), a single dose of hepatotoxic
compounds causes a significant increase in liver lipid
peroxidation in the first 12 h, after which it drops until the
third day after treatment, while GPX activity increases
significantly at the same time. This is in favor of the
glutathione system participation, including GPX, whose
synthesis is increased as the result of enhanced
transcription of the enzyme and, consequently, increased
attenuation of lipid peroxidation.
In the present study, newborn pups were killed not
later than 18 h after birth, which is about 8 days after the
last drug administration. Such timing enables analysis
during the late phase of defense against hepatotoxicity,
which means that the phase of increased lipid peroxida-
tion in the liver has already ended. What follows is the
increased transcription of enzymes GPX and gamma-
glutamyl transpeptidase, which inhibit glutathione synth-
esis in the liver. In the current study, only transplacental
exposure of newborn pups to paracetamol and combined
exposure to paracetamol and 5-nitrofurantoin significantly
decreased levels of GPX. All compounds tested signifi-
cantly decreased MDA levels, but the most pronounced
effect was detected in the case of paracetamol and
combined exposure to paracematol and 5-nitrofurantoin.
Excessive doses of paracetamol deplete glutathione
reserves, and the reactive paracetamol metabolite N-
acetyl-p-benzoquinoneimine easily binds to proteins and
DNA, causing significant liver damage (36). According to
our results, no synergy or antagonism can be detected by
applied methods for combined transplacental exposure to
paracetamol and 5-nitrofurantoin by the methods used.
Therefore, the reduction of GPX reflected systemic
oxidative stress, which is known to occur with the
paracetamol treatment, while the reduction of MDA in
the liver can be interpreted as an unspecific reaction to
the various drug treatments that might have cytotoxic, and
in particular hepatotoxic, effects associated with oxidative
stress and lipid peroxidation. Therefore, of additional
value would be immunohistochemical analyses of differ-
ent organs and tissues for MDA and other biomarkers of
lipid peroxidation, in particular HNE. HNE is known to act
as a bifunctional, concentration- and cytokine-dependent
growth regulator that might also affect glutathione
metabolism and trigger hormetic antioxidant responses
to severe stress (37), which might eventually be involved
in consequential lowering of liver MDA, as was observed
in the study. It is worth mentioning also that placental HNE
was found recently to be related to reduced fetal growth
rate in humans (38), but such analyses could not have
been done in the current study, due to technical limitations
of the immunohistochemical method based on mice
monoclonal antibodies (39). However, in future studies
we will try to extend the present study also in this direction
and evaluate the possible involvement of HNE in the
toxicity of drugs crossing the transplacental barrier.
This is the first study of genome damage in pups
caused by transplacental exposure during organogenesis
using an in vivo MN assay. The advantage of a small
sample size required by this method additionally enabled
the comparison of genome damage in pregnant dams and
their own pups, unlike other genotoxicological methods
where the sample size necessitates the killing of animals
or may impact the outcome of pregnancy. Results showed
that sodium valproate and 5-nitrofurantoin significantly
increased MN frequency in pregnant dams compared to
controls, unlike fluconazole and paracetamol. The
absence of an increased MN frequency in dams after
exposure to fluconazole and paracetamol and increased
MN frequency in their pups confirmed that genome
damage in the mother cannot be used as a predictor of
genome damage in newborns. This was especially
evident for fluconazole, which caused the highest MN
frequency in pups. A common combined application of
therapy by antibiotics and antipyretics, such as that of 5-
nitrofurantoin and paracetamol, significantly increased
MN frequency in pregnant dams but caused no significant
difference in MN frequency between exposure to 5-
nitrofurantoin and the combined effect of 5-nitrofurantoin
and paracetamol.
In newborn pups, the MN frequency was significantly
higher for all of the compounds tested compared to the
negative control. This shows that all of the compounds
tested passed the placental barrier and caused genotoxic
effects in newborn pups. These findings are in accor-
dance with previous reports that showed that fluconazole
and 5-nitrofurantoin also significantly increased MN
frequency in prepubertal animals (12,17). The combined
effect of 5-nitrofurantoin and paracetamol in pups, the
same as in dams, showed a significantly increased
frequency of MN, but there was no significant difference
in MN frequency between exposure to 5-nitrofurantoin
and the combined effect of 5-nitrofurantoin and para-
cetamol. It could be suggested that the genome damage
caused by these compounds alone or combined follow the
same mechanisms and that these mechanisms are not
age related.
The comparison of the MN frequency in pups with
GPX and MDA did not show a correlation, except for the
synergistic action of 5-nitrofurantoin and paracetamol,
which caused both increased MN frequency and the
lowest MDA level among the compounds tested. The
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described synergisms revealed significant side effects in
the case of combined therapy, with possible health risks
that should be investigated in the future.
Both the observed difference in susceptibility to
xenobiotics between pregnant dams and newborns and
the unsuccessful elimination of genome damage in
developing organisms exposed in utero, lipid peroxida-
tion, and metabolic disturbances measurable in newborns
confirm their specific vulnerability and show the need for
further investigation of these processes.
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